Experimental study of combination therapy with S-1 against pancreatic cancer

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 6, 2009, Pages 1211-1219

  Yoshizawa, Jun ^a   Takizawa, Asako ^b   Takeuchi, Osamu ^b   Hiraku, Osamu ^c   Sasaki, Ken ^c   Morimoto, Yoshihito ^d   Atsuda, Koichiro ^d   Inoue, Gaku ^d   Suzuki, Yukio ^b,d   Asanuma, Fumiki ^b   Yamada, Yoshinori ^b  

^a YOKOHAMA ROSAI HOSPITAL   (Japan)

^b KITASATO INSTITUTE HOSPITAL   (Japan)

^c KITASATO INSTITUTE   (Japan)

^d KITASATO UNIVERSITY   (Japan)

Author keywords

Combination chemotherapy; Gemcitabine; Pancreatic cancer; S 1

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; DOXORUBICIN; GEMCITABINE; IRINOTECAN; MITOMYCIN C; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE CYCLE TREATMENT; NICK END LABELING; NONHUMAN; NUDE MOUSE; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CAMPTOTHECIN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DEOXYCYTIDINE; DOXORUBICIN; DRUG COMBINATIONS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; FLUOROURACIL; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MICE, INBRED BALB C; MITOMYCIN; OXONIC ACID; PACLITAXEL; PANCREATIC NEOPLASMS; PYRIDINES; TEGAFUR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 69049084483     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-0990-0     Document Type: Article

References (23)

1. A Jemal R Siegel E Ward Y Hao J Xu T Murray MJ Thun 2008 Cancer statistics, 2008 CA Cancer J Clin 58 71 96
2. HA Burris III MJ Moore J Andersen MR Green ML Rothenberg MR Modiano MC Cripps RK Portenoy AM Storniolo P Tarassoff R Nelson FA Dorr CD Stephens DD Von Hoff 1997 Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 2403 2413
3. S Boeck V Heinemann 2008 The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer Future Oncol 4 41 50
4. M Fukushima H Satake J Uchida Y Shimamoto T Kato T Takechi H Okabe A Fujioka K Nakano H Ohshimo S Takeda T Shirasaka 1998 Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts Int J Oncol 13 693 698
5. K Tatsumi M Fukushima T Shirasaka S Fujii 1987 Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts Jpn J Cancer Res 78 748 755
6. T Shirasaka Y Shimamoto M Fukushima 1993 Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats Cancer Res 53 4004 4009
7. T Okusaka A Funakoshi J Furuse N Boku K Yamao S Ohkawa H Saito 2008 A late phase II study of S-1 for metastatic pancreatic cancer Cancer Chemother Pharmacol 61 615 621
8. T Nagakawa M Kayahara T Ohta H Kitagawa K Mikami T Kurata S Otsuji 2000 Dihydropyrimidine dehydrogenase activity in human pancreatic tumor tissues Cancer Invest 18 516 520
9. H Kuramochi K Hayashi K Uchida G Nakajima T Hatori KD Danenberg PV Danenberg M Yamamoto 2008 High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1 Cancer Chemother Pharmacol 63 85 89
10. K Nakamura T Yamaguchi T Ishihara K Sudo H Kato H Saisho 2006 Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer Br J Cancer 94 1575 1579
11. H Ueno T Okusaka M Ikeda Y Ishiguro C Morizane J Matsubara J Furuse H Ishii M Nagase K Nakachi 2005 A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer Oncology 69 421 427
12. M Tsujie S Nakamori S Nakahira S Takeda Y Takahashi N Hayashi J Okami H Nagano K Dono K Umeshita M Sakon M Monden 2006 Schedule-dependent therapeutic effects of gemcitabine combined with uracil-tegafur in a human pancreatic cancer xenograft model Pancreas 33 142 147
13. LW Hertel GB Boder JS Kroin SM Rinzel GA Poore GC Todd GB Grindey 1990 Evaluation of the antitumor activity of gemcitabine (2′, 2′-difluoro-2′-deoxycytidine) Cancer Res 50 4417 4422
14. X Chen LJ Ko L Jayaraman C Prives 1996 p53 Levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells Genes Dev 10 2438 2451
15. E Rozenblum M Schutte M Goggins SA Hahn S Panzer M Zahurak SN Goodman TA Sohn RH Hruban CJ Yeo SE Kern 1997 Tumor-suppressive pathways in pancreatic carcinoma Cancer Res 57 1731 1734
16. P Gazzaniga I Silvestri A Gradilone S Scarpa S Morrone O Gandini W Gianni L Frati AM Agliano 2007 Gemcitabine-induced apoptosis in 5637 cell line: an in-vitro model for high-risk superficial bladder cancer Anticancer Drugs 18 179 185
17. R Kurdow B Schniewind S Zoefelt L Boenicke AS Boehle P Dohrmann H Kalthoff 2005 Apoptosis by gemcitabine in non-small cell lung cancer cell line KNS62 is induced downstream of caspase 8 and is profoundly blocked by Bcl-xL over-expression Langenbecks Arch Surg 390 243 248
18. F Bunz PM Hwang C Torrance T Waldman Y Zhang L Dillehay J Williams C Lengauer KW Kinzler B Vogelstein 1999 Disruption of p53 in human cancer cells alters the responses to therapeutic agents J Clin Invest 104 263 269
19. RG Morgan 1989 Leucovorin enhancement of the effects of the fluoropyrimidines on thymidylate synthase Cancer 63 1008 1012
20. WB Parker YC Cheng 1990 Metabolism and mechanism of action of 5-fluorouracil Pharmacol Ther 48 381 395
21. S Spiegelman R Nayak R Sawyer R Stolfi D Martin 1980 Potentiation of the anti-tumor activity of 5FU by thymidine and its correlation with the formation of (5FU)RNA Cancer 45 1129 1134
22. W Plunkett P Huang YZ Xu V Heinemann R Grunewald V Gandhi 1995 Gemcitabine: metabolism, mechanisms of action, and self-potentiation Semin Oncol 22 3 10
23. DR Rauchwerger PS Firby DW Hedley MJ Moore 2000 Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity Cancer Res 60 6075 6079